Venous Thromboembolism Risk Assessment and Prophylaxis: A Comprehensive Systematic Review of the Facilitators and Barriers to Healthcare Worker Compliance with Clinical Practice Guidelines in the acute care setting. Reviewers Sherryl Gaston RN BN AFAAQHC CF-JBI 1 1. MClinSc Candidate, The Joanna Briggs Institute, The Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia.sherryl.gaston@unisa.edu.au Margaret Walker RN BSc 2 2. MClinSc Candidate, The Joanna Briggs Institute, The Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia. Margaret.Walker@health.sa.gov.au Principal Supervisor: Dr Sarahlouise White BSc (Hons) PhD, Research Fellow, The Joanna Briggs Institute, The Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia. Associate Supervisor: Dr Gary Misan BPharm PhD, Associate Research Professor, Centre for Rural Health and Community Development (UniSA), Adjunct Associate Professor Research, Spencer Gulf Rural health School, The University of Adelaide and University of South Australia Review question/objective The objective of this review is to identify, appraise and synthesise the best available evidence on the facilitators and barriers to compliance with Venous Thromboembolism (VTE) risk assessment and prophylaxis clinical practice guidelines in the acute care setting. More specifically, the review question is: To what extent are clinical practice guidelines for risk assessment and prophylaxis of VTE adhered to in the acute care setting, and what are the facilitators and barriers? Background Venous Thromboembolism (VTE) is the collective name for Deep Vein Thrombosis and Pulmonary Embolism. 1 A deep vein thrombosis (DVT) occurs when a blood clot forms in the deep veins of the leg and sometimes the pelvis. 1 A pulmonary embolism (PE) occurs where some or all of the clot breaks Page 1
away and moves from the vein, to cause an obstruction in the pulmonary artery or its branches in the lungs. 1 A DVT may cause leg swelling, tenderness and pain, with a PE showing signs of chest pain, bloody sputum, shortness of breath and heart failure. 1 There are instances where there are no signs or symptoms and diagnosis is made after a person dies. 1 There are two main categories of risk factors for VTE. The first is those associated with the clinical setting such as surgery and type of surgery, for example, major surgery with medical risk factors, immobilisation and immobilising treatments, medical patients with additional risk factors, some fractures, stroke, some chemotherapy treatment, acute spinal injury or multiple trauma. 2 The second category relates to patient factors, such as age, previous history of DVT/PE, past history of major surgery, recent pregnancy, malignancy, obesity, oral contraceptive or hormone replacement, inflammatory bowel disease, as well as any thrombophilia conditions. 2 There are a number of other risk factors that have been described (see Table 1 in Appendix 1). In 2008, approximately 9,250 cases of VTE in females and 5,466 cases in males were reported in Australia. This is a total of 14,716 cases of VTE across Australia for the year 2008. 3 and represents an increase in Australia of 2% since 2004-05. In 2003, it was reported that of people who had a DVT about 12% died. 4 PE is reportedly responsible for approximately 10% of all hospital deaths in Australia. 5 The estimated survival rate of those with VTE is 47.5% after 8 years, 53.5% after 5 years and 63.6% after one year. 6 Morbidity for survivors of VTE can be quite debilitating and some of the complications may not occur until weeks or months after the initial blood clot. 7 In the United Kingdom (UK) the population is about three times that of Australia and it is estimated that VTE is responsible for about 25,000 deaths each year. 8 This estimate shows that the incidence of VTE in the UK is 50% greater than in Australia. 8 It is also estimated that about 300,000 people in the United States of America die of VTE each year, which is about four times the death rate in Australia. 9 The incidence of VTE is greater in hospitalised patients than those living in the community who are the same age, and is as much as 100 times higher. 2 A multinational study to investigate the use of prophylaxis for patients that had risk factors for VTE was undertaken. 10 The findings of this study identified a substantial number of hospitalised people at risk globally of developing VTE, and that prophylaxis recommended for their risk factor/s were not adequately utilised. 10 The National Health and Medical Research Council (NHMRC) state that, The incidence of VTE as a complication of hospital admission is commonly underestimated. 2 There is good evidence that VTE prophylaxis measures continue to be under-utilised or used sub-optimally. The National Institute of Clinical Studies estimated that about 2,000 people die as a result of VTE each year with about 30,000 being hospitalised. 2 Of the 2,000 deaths, many are potentially preventable through appropriate risk assessment and the corresponding use of measures like anti-embolic stockings, or antithrombotic drugs. 2
VTE cost the healthcare system about $10,007 for each case and can lead to short term as well as long term morbidity and mortality. 1,3,10 People of working age represented 43% of cases of VTE in 2008. 3 In Australian hospitals in the 2004-05 period the total hospital inpatient expenditure on VTE was $71.04 million. 3 In 2007 it was estimated that for 2008 the total inpatient expenditure for VTE in hospitals would be $81.2 million. 3 These costs did not include any out-of-hospital expenses such as radiology, medical specialists, general practitioner, pathology, pharmaceuticals or allied health. 3 These costs also did not take into account ongoing health system expenditure or associated costs. 3 Not only does VTE affect costs within the health system, it also impacts on the community with costs for carers, productivity losses, equipment for homes or modifications needed as well as costs of people transferring from the workforce to welfare or disability payments. 3 Similar cost findings have been identified in the United States and costs are increasing each year during and after a VTE event. 3 There is a high burden on the healthcare system and health care costs in relation to people developing this disorder globally 10,11 The optimal way to prevent VTE in the acute setting is to undertake a risk assessment on all adult patients as they are admitted 2,10 and then provide any necessary prophylaxis in accordance with that assessment. 1 Research has shown that if appropriate prophylaxis is used for patients considered to be at risk of VTE, there is a significantly reduced incidence of VTE. 10 A risk assessment is a tool that is used to identify indicators of potential risks using standard criteria. 12 It can be used to systematically assess a person s level of risk when they are admitted to hospital. 12 The risk assessments used on hospital patients are developed from the national guidelines and are usually a scoring system to assess the patients risk factors where points are given for specific risks. 13 The points are assigned to each risk factor in relation to the amount they contribute to the risk. 13 Once the risks have been identified the score is calculated giving an overall risk score. 13 The risk assessment form will generally identify guidelines of what prophylaxis should be initiated for different risk factors; these vary slightly in different facilities, however they are basically the same. 13 The only time prophylaxis should not be used is when there is a contraindication and this will be assessed on an individual basis. 13 VTE prophylaxis can be categorised as either mechanical or chemical. 14 Mechanical prophylaxis includes early ambulation, the use of anti-embolic/graduated compression stockings, and/or intermittent pneumatic compression. 14 Encouraging all patients to ambulate and maintain adequate hydration is important regardless of their risk category. 14 Anti-embolic stockings apply graduated pressure from the ankle up the leg, come in knee-high and thigh-high lengths and are to increase the blood flow velocity in the legs. 14 The intermittent pneumatic compression device is to provide effective blood flow from the lower limbs and adjusts itself to the patient s vascular refill time. 14 Chemical prophylaxis is a medication that will prevent or delay the bloods ability to clot with low-dose unfractionated heparin (LDUH) or low molecular weight heparin (LMWH) generally being provided. 14 These medications are predominately provided as a subcutaneous injection, however there are oral products available for specific conditions. 14 To maintain haemostasis the body has a coagulation cascade and the LDUH and LMWH either inhibit or alter different steps in this cascade. 15 Generally Page 3
the risk guidelines will advocate a combination of both mechanical and chemical prophylaxis being used, especially during the high risk period. 14 The NHMRC are one of the groups in Australia responsible for the development of nationally recommended clinical practice guidelines. 2 Clinical practice guidelines are designed to aid healthcare workers improve patient care within recognised standards. 16 Guidelines are generally developed following a review of available evidence in association with clinical experts. 16 By producing national guidelines and encouraging healthcare facilities and professionals to adopt and comply with them, there is some attempt at standardisation of patient care, and ultimately improvements in the quality of delivered care will result. 16 Several countries have venous thromboembolism guidelines to provide a standardised way for risk assessment and prophylaxis use. 2,17 In Australia, the NHMRC have published a Clinical Practice Guideline for the prevention of venous thromboembolism in patients admitted to Australian hospitals. 2 Through this initiative a program called Stop The Clot was developed to assist and support private hospitals in Australia, funded by the Australian Commission on Safety and Quality in Health Care. 11 The National Institute for Clinical Excellence (NICE) developed similar guidelines for hospitals in England and Wales. The NICE guidance has been used to develop a quick reference guide titled Venous thromboembolism: reducing the risk. 17,18 Some barriers have been identified for undertaking VTE risk assessment and initiating prophylaxis. One is that there is a lack of awareness by healthcare professionals about the incidence of VTE and how VTE can manifest after the patient has been discharged from hospital. 11 Another barrier is the lack of education and knowledge about the risk assessment 11 e.g., that a risk assessment tool is available and how to undertake completing it, as well as what prophylaxis should be initiated for which level of risk. 11 Another barrier which may hinder VTE risk assessment is when healthcare professionals dispute or disagree with the clinical practice guidelines, even though they are evidencebased. 11 An additional area identified as being a barrier is inadequate system support for conducting VTE risk assessments. 11 Lack of support can range from a health service having no policies for VTE prophylaxis with no audits to check the reporting system s viability, to different practices in different units within the same organisation, to no clear delegation for the responsibility of completing the risk assessment and initiating prophylaxis. 11 A way to facilitate compliance with clinical practice guidelines is to delegate a staff member to be an authority (or a champion) on the subject. 11 This staff member can then identify and develop ways to motivate other staff to undertake changes in practice, and to employ strategies for staff across the organisation to achieve a consensus on practice. 11 This could be an initiative of the hospital by creating a position for a nurse champion who would be proactive in VTE prophylaxis and provide support and education to other staff in this area. 1 The Safe Medication Practice Unit in Queensland (SMPU) discussed problems with VTE risk assessments being completed for patients. 19 They found that even though nurses are capable of completing risk assessments, doing so increased their workload. 19 The study also reported that depending on the patient s level of VTE risk or individual combination of risk factors, the nurses were unable to initiate all required prophylaxis. 19 It is acknowledged that chemical prophylaxis can only be
prescribed by a medical practitioner, however the nurse as patient advocate is able to identify patient needs and recommend chemical prophylaxis be initiated. 19 The SMPU recommends that medical practitioners be the ones to complete the risk assessment as they state that the best practice guidelines were developed for them. 19 However this may be limiting for some rural and/or remote hospitals that are staffed primarily by nurses, with general practitioners having hospital rights which means that they are only available at set or limited times, while attending patient consults in their office at other times. 20 Nurses are the largest professional group within the healthcare system with direct patient care, 21 therefore nurses can have an integral role in implementing the risk assessment and influencing prophylaxis used. 21 A research project using a patient case note audit was undertaken in a Queensland hospital between 2005 and 2009. This study showed an increase of appropriate prophylaxis being used in patients admitted to the hospital from 27% to 85% over the five year period. 1 This improvement was reportedly due to evidence based education sessions which empowered nurses to take responsibility for undertaking VTE risk assessments. 10 There has been a search of the Joanna Briggs Institute Library of Systematic Reviews, the Cochrane Database of Systematic Reviews, PubMed and CINAHL for systematic reviews on this topic and there was one found that overlaps with this one. This review was on Strategies to improve prophylaxis for Venous Thromboembolism in hospitals, and the systematic review covered the time period from 1996 to May 2003. 22 Therefore this review will commence from May 2003 to November 2011. The aim of the current systematic review is to extend knowledge from the previous systematic review by focussing on the facilitators and barriers to healthcare worker compliance with national guidelines for VTE risk assessments and prophylaxis. Inclusion criteria Types of participants This review will consider any studies that include all health care professionals regardless of their designated involvement with venous thromboembolism risk assessment and prophylaxis in the acute care setting. Phenomena of interest This review will consider studies that evaluated the facilitators and barriers to venous thromboembolism compliance with clinical practice guidelines in the acute care setting. Page 5
The qualitative component of the review will consider as phenomena of interest any studies that identify facilitators and/or barriers to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. The quantitative component of the review will consider any studies that report on the barriers and facilitators to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. The textual component of the review will consider any paper that discusses the facilitators and/or barriers to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. Types of outcomes This review will consider studies that include measures of compliance as their outcome measures. The qualitative component of the review will consider any studies that identify facilitators and/or barriers to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. The quantitative component of the review will consider any studies that report on the barriers and facilitators to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. The textual component of the review will consider any paper that discusses the facilitators and/or barriers to compliance with clinical practice guidelines in relation to venous thromboembolism risk assessment and prophylaxis in the acute care setting. Types of studies The qualitative component of the review will consider studies that focus on qualitative data including, but not limited to, designs such as phenomenology, grounded theory, ethnography, action research and feminist research. In the absence of research studies, other text such as opinion papers and reports will be considered. The quantitative component of the review will consider both experimental and epidemiological study designs including randomised controlled trials, non-randomised controlled trials, quasi-experimental, before and after studies, prospective and retrospective cohort studies, case control studies and analytical cross sectional studies. In the absence of research studies, other text such as opinion papers and reports will be considered.
The textual component of the review will consider expert opinion, discussion papers, position papers and other text. Search strategy The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilised in this review. An initial limited search of MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe the article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference lists of all identified reports and articles will be searched for additional studies. Studies published in English will be considered for inclusion in this review, as well as studies published between May 2003 and November 2011. These dates were identified due to a systematic review on a similar topic that overlaps this review. 22 The databases to be searched include: PubMed CINAHL EMBASE Scopus The search for unpublished studies will include: ProQuest (for dissertations and theses) Mednar Initial search terms to be used will be: Venous Thromboembolism (VTE, DVT, PE) Deep vein thrombosis Pulmonary embolism Risk Assessment Guidelines Compliance Prophylaxis Page 7
Nurse/Doctor Healthcare worker/professional Facilitators and Barriers Assessment of methodological quality Qualitative papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Qualitative Assessment and Review Instrument (JBI-QARI) (Appendix II). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer. Quantitative papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix II). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer. Textual papers selected for retrieval will be assessed by two independent reviewers for authenticity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Narrative, Opinion and Text Assessment and Review Instrument (JBI-NOTARI) (Appendix II). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer. Data collection Qualitative data will be extracted from papers included in the review using the standardised data extraction tool from JBI-QARI (Appendix III). Quantitative data will be extracted from papers included in the review using the standardised data extraction tool from JBI-MAStARI (Appendix III). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives. Textual data will be extracted from papers included in the review using the standardised data extraction tool from JBI-NOTARI (Appendix III).
Data synthesis Qualitative research findings will, where possible, be pooled using JBI-QARI. This will involve the aggregation or synthesis of findings to generate a set of statements that represent that aggregation, through assembling the findings rated according to their quality, and categorising these findings on the basis of similarity in meaning. These categories will then be subjected to a meta-synthesis in order to produce a single comprehensive set of synthesised findings that can be used as a basis for evidence-based practice. Where textual pooling is not possible the findings will be presented in narrative form. Quantitative papers will, where possible be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square and also explored using subgroup analyses based on the different quantitative study designs included in this review. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. Textual papers will, where possible, be pooled using JBI-NOTARI. This will involve the aggregation or synthesis of conclusions to generate a set of statements that represent that aggregation, through assembling and categorising these conclusions on the basis of similarity in meaning. These categories will then be subjected to a meta-synthesis in order to produce a single comprehensive set of synthesised findings that can be used as a basis for evidence-based practice. Where textual pooling is not possible the conclusions will be presented in narrative form. Conflicts of interest There is no conflict of interest Acknowledgements As this systematic review will form part of the submission for the award of Masters in Clinical Science for the primary reviewer, a secondary reviewer will only be used for critical appraisal. Page 9
References 1. Collins R, MacLellan L, Gibbs H, MacLellan D, Fletcher J. Venous Thromboembolism prophylaxis: The role of the nurse in changing practice and saving lives. Australian Journal of Advanced Nursing [Internet]. 2010 [cited 2010 Aug 24];27(3): pp. 83-89. Available from: http://www.ajan.com.au/vol27/27-3_collins.pdf 2. National Health and Medical Research Council (NHMRC), Clinical Practice Guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian Hospitals, Commonwealth of Australia, ACT. [Internet]. 2009 [cited 2009 July 28] pp. 11-23 Available from: http://www.nhmrc.gov.au/guidelines/publications/cp115 3. Access Economics, The burden of venous thromboembolism in Australia, Report for the Australian and New Zealand Working Party on the management and prevention of venous thromboembolism. March. [Internet] 2008 [cited 2010 Nov 19] pp. vi, 14-15. Available from: http://www.mpdgp.com.au/ 4. White RH. The epidemiology of venous thromboembolism, Circulation. American Heart Association. 107(23 suppl 1):[Internet] 2003 [cited 2011 Sept 21] pp 14-8 Available from: http://www.circulationaha.org 5. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic Burden of Deep-vein Thrombosis, Pulmonary Embolism, and Post-thrombotic Syndrome. American Journal of Health-system Pharmacy. 63(20): [Internet] 2006 [cited 2011 Sept 21] pp. S5-S15 Available from: http://www.medscape.com/viewarticle/547258_1 6. Ageno W, Squzzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism, Seminars in Thrombosis And Hemostasis, vol 32, issue 7: [Internet] 2006 [cited 2011 Sept 21] pp651-658 Available from: www.mendeley.com 7. Hirsch J, Hoak J. Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation. 93 (12): [Internet] 1996 [cited 2011 Sept 21] pp 2212-2245 Available from: http://www.circulationaha.org
8. Coombes R. Venous thromboembolism caused 25000 deaths in a year, says MP s. British Medical Journal 330:559 [Internet] 2005 [cited 2011 Sept 21] Available from: http://www.bmj.com/cgi/content/full/330/7491/559-c?ehom 9. Moll S, Mackman N. Venous Thromboembolism: A need for more Public Awareness and research into mechanisms, Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association. 28: [Internet] 2008 [cited 2011 Sept 21] pp. 367-369 Available from: http://atvb.ahajournals.org/content/28/3/367 10. Cohen A, Tapson V, Bergmann J, Goldhaber S, Kakkar A, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study, The Lancet, vol 371. [Internet] 2008 [cited 2010 Dec 1] pp. 750-759 Available from: www.thelancet.com 11. National Institute of Clinical Studies (NICS), Stop the Clot: Integrating VTE prevention guideline recommendations into routine hospital care, National Health and Medical Research Council, Canberra. [Internet] 2008 [cited 2010 July 28] Available from: http://www.nhmrc.gov.au/nics/nics-programs/vte-prevention-guideline/nics-vteprevention-programs-australian-hospitals/stop-c 12. Hairon, N. New risk assessment tool aims to help nurses prevent VTE, NursingTimes.net [Internet] 2008 [cited 2011 Sept 14] Available from: 13. http://www.nursingtimes.net/new-risk-assessment-tool-aims-to-help-nursesprevent-vte/1883522.article 14. Nutescu EA. Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches. American Journal of Health-system Pharmacists. Vol 64, issue 11, Supplement 7. [Internet] 2007 [cited 2011 Sept 21] 15. The Australia & New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. Prevention of Venous Thromboembolism. Health Education & Management Innovations, Australia. 2010 [cited 2010 July 26] Page 11
16. Melnikova I. News & Analysis: The anticoagulants market. Nature Reviews, Macmillan Publishers Limited. Vol 8. [Internet] 2009 [cited 2011 Sept 21] Available from: http://www.nature.com/nrd/journal/v8/n5/pdf/nrd2851.pdf 17. Farquhar CM, Kofa EW, Slutsky JR. Clinicians attitudes to clinical practice guidelines: a systematic review. The Medical Journal of Australia, 177 (9): [Internet] 2002 [cited 2011 Sept 21] pp. 502-506 Available from: http://www.mja.com.au/public/issues/177_09_041102/far10064_fm.html 18. National Institute for Health and Clinical Excellence (NICE), Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolus) in patients admitted to hospital. National Clinical Guideline Centre acute and chronic conditions, Regents Park, London. [Internet] 2010 [cited 2010 Aug 11] Available from: http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf 19. National institute for Health and Clinical Excellence (NICE), Quick Reference Guide: Venous Thromboembolism: reducing the risk. National Clinical Guideline Centre acute and chronic conditions, Regents Park, London. [Internet] 2010 [cited 2010 Aug 11] Available from: http://www.nice.org.uk/nicemedia/live/12695/47197/47197.pdf 20. Schluter J, Scotter H, Chaboyer W. Best practice guidelines for Australia and New Zealand on the prevention of venous thromboembolism: Issues and implications for nurses. Contemporary Nurse. Volume 29. Issue 1. [Internet] 2008 [cited 2011 July 19] Available from: http://www.health.qld.gov.au/patientsafety/documents/vet.pdf 21. Bourke L, Sheridan C. Understanding rural health key concepts, in Liaw S-T, Kilpatrick, S, editors. A Textbook of Australian Rural Health, Australian Rural Health Education Network, Canberra, 2008 22. Schober, M. The Global Emergence of Advanced Practice Nurses in Providing Home and Community Health Care Services. Home Health Care Management Practice, 20(1):34-40. [Internet] 2007 [cited 2011 Sept 21] Available from: http://hhc.sagepub.com/content/20/1/34.full.pdf 23. Tooher R, Middleton P, Pham C, Fitridge R, Rowe S, Babidge W, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Annals of
Surgery. Vol 241, Number 3. [Internet] 2005 [cited 2010 July 26] pp. 397-415 Available from: Lippincott Williams & Wilkins. Page 13
Appendix I - Risk factors for venous thromboembolism National Health and Medical Research Council (NHMRC), Clinical Practice Guideline for the prevention or venous Thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian Hospitals, Commonwealth of Australia, ACT. [Internet] 2009 [cited 2010 July 28] Available from: http://www.nhmrc.gov.au/guidelines/publications/cp115 National Clinical Guideline Centre Acute and Chronic conditions. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. [Internet] 2010 [cited 2011 Sept 20] Available from: http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf Table 1 Individual Patient Risk Factors Clinical Setting Risk Factors Age (VTE risk increases after the age of 40 and greater over 60 years) All surgical procedures especially orthopaedic, Previous history of DVT/PE pelvic, thoracic and abdominal Family history of VTE Immobilisation especially if it is prolonged Acute medical illness Major surgery with medical risk factors Pregnancy or recent birth Some fractures History of varicose veins Acute spinal injury or multiple trauma Malignancy or cancer treatment Some forms of chemotherapy Obesity Oral contraceptive or hormone replacement therapy Thrombophilia conditions either inherited or acquired Inflammatory bowel disease Previous major surgery Stroke causing immobility Heart conditions including myocardial infarction, heart failure Chest infections either acute or acute on chronic Other severe infection From the National Health and Medical Research Council and National Clinical Guideline Centre Acute and Chronic conditions
Appendix II JBI Critical appraisal instruments Page 15
Page 17
Page 19
Appendix III JBI Data extraction instruments
Page 21
Page 23
t page break Page 25